FDA says again: Rosiglitazone does not up CV risk 

The first day of a two-day meeting on rosiglitazone included presentations from the FDA, GlaxoSmithKline, Duke University reviewers, and one dissenting FDA official. Today the panel will vote on the drug's future.

Source: theHeart.org - June 6, 2013 Category: Cardiology Source Type: news